When considering all CLL patients, we found that SLC7A5 + URAHP + FAM166A/CNTNAP2 + HOMER3 + MACC1 (AUC 80.33%) is the best combination of genes considered for predicting relapse events within 15–18 months. This evidence concerns the gene MACC1 and B-cell chronic lymphocytic leukemia.